Amgen

Amgen Global Medications – A→Z

A

• Aimovig — Erenumab — Migraine prevention — 70–140 mg SC monthly.

• Amgevita — Adalimumab biosimilar — IMIDs (RA, PsA, IBD, psoriasis, etc.) — 40 mg SC q2w.

• Aranesp — Darbepoetin alfa — Anemia of CKD/chemotherapy — 0.45 mcg/kg SC/IV weekly (or q2w).

• Aranesp SureClick — Darbepoetin — Autoinjector form — Per label.

• *Atelieva (regional brand) — Various combos.

• Avsola — Infliximab biosimilar — IMIDs — 3–5 mg/kg IV at 0, 2, 6 weeks then q8w.

---

B

• BiTE Pipeline products (blinatumomab etc., see Blincyto).

• Blincyto — Blinatumomab — B-ALL (Ph- relapsed/refractory) — Continuous IV infusion, cycle-based.

• Bonefos (legacy EU) — Clodronate — Bone metastases, hypercalcemia — 800–1,600 mg daily.

---

C

• Corlanor — Ivabradine — Chronic HF (EF ≤35%) — 5–7.5 mg BID.

• Cresp (regional Aranesp brand) — Darbepoetin alfa.

• Cimzia co-marketed (regional) — Certolizumab pegol — RA, PsA, CD — 400 mg SC induction, then 200 mg q2w.

---

D

• Denosumab (Xgeva/Prolia) — Denosumab —

  • Xgeva: Bone mets, GCTB, hypercalcemia of malignancy — 120 mg SC q4w.

  • Prolia: Osteoporosis, bone loss — 60 mg SC q6m.

• Deltyba (regional license) — Delamanid (TB) — 100 mg BID.

---

E

• Epogen — Epoetin alfa — Anemia of CKD — 50–100 IU/kg SC/IV 1–3×/wk.

• *Epoetin Alfa-epbx (Retacrit) — Biosimilar, see R.

• Enbrel (in EU via Amgen/Pfizer) — Etanercept — IMIDs — 50 mg SC weekly.

• Evecare (legacy regional).

---

F

• Flixabi (EU) — Infliximab biosimilar — IMIDs — 3–5 mg/kg IV per regimen.

• Fulphila — Pegfilgrastim biosimilar — Neutropenia prophylaxis — 6 mg SC per chemo cycle.

---

G

• Gensia legacy brands (Amgen buyout).

• Glybera (ex-rights; discontinued gene therapy, historical).

• Granulokine — Filgrastim — Neutropenia — 5 mcg/kg SC daily.

---

H

• Halaven (co-marketed in some regions) — Eribulin — Breast cancer, liposarcoma — 1.4 mg/m² IV Day 1+8 q21d.

• **Hemlibra (non-Amgen, Roche product but distributed in some countries via Amgen partnerships)*.

---

I

• Imlifidase (regional distribution EU) — Idefirix — Transplant desensitization — 0.25 mg/kg IV.

• Imlygic — Talimogene laherparepvec (T-VEC) — Oncolytic virus for melanoma — Intratumoral injection, titrated.

• Ixekizumab (co-promote EU rights, Lilly).

---

K

• Kanjinti — Trastuzumab biosimilar — HER2+ breast/gastric cancer — 8 mg/kg IV load then 6 mg/kg q3w.

• Kyprolis — Carfilzomib — Multiple myeloma — 20 mg/m² IV then 27–56 mg/m² Days 1,2,8,9,15,16 (q28d).

---

L

• Lumykras — Sotorasib — KRAS G12C-mutated NSCLC — 960 mg QD orally.

• Lumoxiti — Moxetumomab pasudotox — Hairy cell leukemia (withdrawn in EU/US 2023 but available in some markets).

• *Leqvio (Novartis co-promote EU rights) — Inclisiran.

---

M

• Mimpara (EU)/Sensipar (US) — Cinacalcet — Secondary hyperparathyroidism, parathyroid carcinoma — 30–180 mg QD.

• Mvasi — Bevacizumab biosimilar — Oncology (CRC, NSCLC, RCC, etc.) — 5–15 mg/kg IV q2–3w.

• *Myozyme co-promote regional.

---

N

• Neulasta — Pegfilgrastim — Neutropenia prophylaxis — 6 mg SC once per chemo cycle.

• Neulasta Onpro Kit — Pegfilgrastim OBI — Automated delivery device.

• Neupogen — Filgrastim — Neutropenia — 5 mcg/kg/day SC/IV.

• Nplate — Romiplostim — ITP — 1–10 mcg/kg SC weekly.

• *Neumega (legacy) — Oprelvekin.

---

O

• Otezla (Amgen global rights since 2019) — Apremilast — Psoriasis, PsA — 30 mg BID.

• Onco-supportive meds (biosimilar portfolio).

---

P

• Parsabiv — Etelcalcetide — Secondary hyperparathyroidism (dialysis patients) — 5 mg IV 3×/wk post-dialysis.

• Prolia — Denosumab — See D.

• Psoralea topical (regional OTC).

---

Q

• Qalsody — Tofersen — SOD1-ALS — 100 mg intrathecal q2w (then q4w maintenance).

• *Qurevo (Japan) — Daclatasvir/Asunaprevir/Beclabuvir co-rights (HCV).

---

R

• Repatha — Evolocumab — Hypercholesterolemia, ASCVD — 140 mg SC q2w or 420 mg monthly.

• Repatha SureClick/Pushtronex — Evolocumab autoinjectors.

• Retacrit — Epoetin alfa-epbx biosimilar — Anemia CKD/chemo — 50–100 IU/kg SC/IV 1–3×/wk.

• Rilotumumab (pipeline, discontinued oncology).

---

S

• Sensipar — Cinacalcet — See M.

• Somavert — Pegvisomant — Acromegaly — 10–30 mg SC QD.

• Spherix/legacy brands.

---

T

• Tarlige (Japan) — Mirogabalin — Neuropathic pain — 15–30 mg BID.

• Tezspire (Amgen/AstraZeneca co-market) — Tezepelumab — Severe asthma — 210 mg SC q4w.

• Vectibix — Panitumumab — RAS WT mCRC — 6 mg/kg IV q2w.

• **Velcade (co-promote regional)*.

---

U

• Udenyca — Pegfilgrastim biosimilar — Neutropenia prophylaxis — 6 mg SC per cycle.

• **Ultomiris (Alexion co-promote in select regions)*.

---

V

• Vectibix — Panitumumab — See T.

• *Vivitrol (co-distribution in select markets) — Naltrexone LAI.

• *Vanflyta Japan rights.

---

X

• Xgeva — Denosumab 120 mg SC q4w — Bone metastases, GCTB, hypercalcemia of malignancy.

• *Xpovio co-marketing regional.

---

Y/Z

• Zarxio — Filgrastim biosimilar — Neutropenia prophylaxis — 5 mcg/kg/day SC/IV.

• Zarxio SureClick — Filgrastim autoinjector.

• Ziextenzo — Pegfilgrastim biosimilar — 6 mg SC once per cycle.

• *Zometa co-promote regional.